Pilot Project for Graves Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Graves Disease+3 More
Cervical Collar Therapy Indicator (COTI) - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a device that is worn around the neck and measures radioiodine exposure to help estimate the amount of iodine-131 that a person needs for treatment of thyroid disorders while minimizing risks of comorbidities.

Eligible Conditions
  • Graves Disease
  • Thyroid Cancers

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 9-12 months

6-9 months
Evaluation of the Variability in radioiodine kinetics for patients with thyroid cancer and graves disease
9-12 months
Validation of the device as an enhancement of quantitative measurements in patients with Graves disease and thyroid cancer

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Pilot Project
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Pilot Project · No Placebo Group · N/A

Pilot Project
Device
Experimental Group · 1 Intervention: Cervical Collar Therapy Indicator (COTI) · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 9-12 months

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,058 Previous Clinical Trials
31,003,967 Total Patients Enrolled
Prasanna Santhanam, MBBS, MDPrincipal InvestigatorJohns Hopkins University

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients are able to understand English and able to follow instructions.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: November 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.